You can buy or sell NLNK and other stocks, options, ETFs, and crypto commission-free!
NewLink Genetics Corporation Common Stock, also called NewLink Genetics, is a late-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of novel immunotherapeutic products to improve cancer treatment options for patients and physicians. Read More The firm's portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a range of oncology indications. It products include HyperAcute Pancreas, HyperAcute Lung, HyperAcute Melanoma, HyperAcute Imunotherapies, NLG8189, and IDO Pathway Inhibitors. The company was founded by Charles J. Link and Nicholas N. Vahanian on June 4, 1999 and is headquartered in Ames, IA.
52 Week High
52 Week Low
Stock Price, News, & Analysis for NewLink Genetics
NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer.
Simply Wall StMar 2
NewLink Genetics Corporation (NASDAQ:NLNK): Is It A Good Long Term Opportunity?
The latest earnings release NewLink Genetics Corporation’s (NASDAQ:NLNK) announced in December 2018 showed company earnings became less negative compared to the previous year’s level – great news for investors Below is a brief commentary on my key takeaways on how market analysts perceive NewLink Genetics’s earnings growth trajectory over the next few years and whether the future looks brighter.
Expected May 2, After Hours